Session » Vasculitis – ANCA-Associated Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0735

ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0732

Antineutrophil Cytoplasmic Antibodies and Associated Vasculitis According to Clinical Phenotypes: A Single-Center Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0730

Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes

10:30AM-12:30PM: Abstract Number: 0717

Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020

10:30AM-12:30PM: Abstract Number: 0731

Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms

10:30AM-12:30PM: Abstract Number: 0715

Diffuse Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Revisited

10:30AM-12:30PM: Abstract Number: 0721

Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study

10:30AM-12:30PM: Abstract Number: 0729

Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results

10:30AM-12:30PM: Abstract Number: 0722

Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0728

Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis

10:30AM-12:30PM: Abstract Number: 0720

Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care

10:30AM-12:30PM: Abstract Number: 0718

Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic

10:30AM-12:30PM: Abstract Number: 0724

Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study

10:30AM-12:30PM: Abstract Number: 0733

Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)

10:30AM-12:30PM: Abstract Number: 0734

Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 0726

Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 0716

Outcomes of COVID-19 in Patients with ANCA-Associated Vasculitis (AAV)

10:30AM-12:30PM: Abstract Number: 0727

Prospective Cellular Biomarkers in ANCA Associated Vasculitis: A Pilot Study

10:30AM-12:30PM: Abstract Number: 0719

Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease

10:30AM-12:30PM: Abstract Number: 0725

Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0723

Sociodemographic Factors Associated with Clinic Non-attendance and Unscheduled Emergency Care Episodes in ANCA-associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0714

Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation

« View all sessions from this meeting